research use only

Fenofibric acid PPAR inhibitor

Cat.No.S4527

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.
Fenofibric acid PPAR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 318.75

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 318.75 Formula

C17H15ClO4

Storage (From the date of receipt)
CAS No. 42017-89-0 Download SDF Storage of Stock Solutions

Synonyms NSC 281318, Trilipix, FNF acid Smiles CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl

Solubility

In vitro
Batch:

DMSO : 64 mg/mL (200.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
PPARα [1]
In vitro
Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR[1].
In vivo
Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of this compound on EPC mobilization in the OIR model is PPARα-dependent. It inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. This chemical decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03382756 Completed
Dyslipidemias
Chong Kun Dang Pharmaceutical
October 12 2017 Phase 1
NCT03515213 Completed
Huntington Disease
University of California Irvine
April 27 2017 Phase 2
NCT02891408 Completed
Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences
September 23 2016 Phase 1
NCT02651753 Completed
Dyslipidemia
Chong Kun Dang Pharmaceutical
January 2016 Phase 1
NCT02422030 Completed
Healthy
Chong Kun Dang Pharmaceutical
March 17 2015 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map